NSCLC Archives - Page 2 of 4 -

Interview: AZ’s immunotherapy gamble starts to pay off

https://pharmaphorum.com/views-and-analysis/az-immunotherapy-gamble-pays-off/

Tagrisso on target to be EGFR+ lung cancer standard

https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/

Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

https://pharmaphorum.com/news/roches-alecensa-shows-big-benefit-brain-mets-advanced-lung-cancer/

Evolving immunotherapy strategies in NSCLC

https://pharmaphorum.com/views-and-analysis/evolving-immunotherapy-strategies-nsclc/

Roche raises outlook for 2017 following strong launches

https://pharmaphorum.com/news/roche-raises-outlook-2017-following-strong-launches/

ASCO 2017: Breast cancer next target for Keytruda

https://pharmaphorum.com/views-and-analysis/asco-2017-breast-cancer-keytruda/

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

https://pharmaphorum.com/news/bms-looks-opdivo-cancer-vaccine-combination-regain-ground-nsclc/

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

https://pharmaphorum.com/news/roches-alecensa-beats-xalkori-lung-cancer-head-head/

Novartis’ Zykadia gets fast first-line lung cancer review

https://pharmaphorum.com/news/novartis-zykadia-gets-fast-first-line-lung-cancer-review/

Search